Provided by Tiger Trade Technology Pte. Ltd.

Cytosorbents

0.6836
-0.0264-3.72%
Post-market: 0.68990.0063+0.92%19:10 EST
Volume:159.53K
Turnover:107.45K
Market Cap:42.93M
PE:-4.01
High:0.7200
Open:0.7200
Low:0.6301
Close:0.7100
52wk High:1.61
52wk Low:0.6000
Shares:62.80M
Float Shares:54.98M
Volume Ratio:1.41
T/O Rate:0.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1705
EPS(LYR):-0.3806
ROE:-93.26%
ROA:-19.01%
PB:4.76
PE(LYR):-1.80

Loading ...

CytoSorbents Corporation Receives Nasdaq Notice for Non-Compliance with $1 Minimum Bid Price Requirement

Reuters
·
Oct 04

CytoSorbents Unveils New Clinical Trial Data on CytoSorb® and DrugSorb™-ATR for Cardiac Surgery at EACTS 2025 Annual Meeting

Reuters
·
Sep 29

Cytosorbents Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Sep 16

Cytosorbents Corp - Will Not File Final Appeal With Cdrh in Relation to Drugsorb-Atr

THOMSON REUTERS
·
Sep 16

Cytosorbents Provides Drugsorb-Atr Regulatory Update

THOMSON REUTERS
·
Sep 16

Cytosorbents - Plans Pre-Submission Meeting Request With FDA Next Month; Formal Meeting Anticipated in Q4

THOMSON REUTERS
·
Sep 16

Cytosorbents Corp - Withdraws Request for Reconsideration With Health Canada

THOMSON REUTERS
·
Sep 16

Cytosorbents Corp - Plans New De Novo Application

THOMSON REUTERS
·
Sep 16

CytoSorbents Corporation to Host Global Webinar on Sepsis and Septic Shock Insights

Reuters
·
Sep 08

CytoSorbents Corporation to Present at H.C. Wainwright 27th Annual Global Investment Conference

Reuters
·
Sep 05

CytoSorbents Corporation Reports Q2 2025 Revenue of $9.6M, Up 9% Year-Over-Year, Led by 22% Growth in Germany Sales

Reuters
·
Aug 28

Cytosorbents Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Aug 20

BRIEF-Cytosorbents Updates U.S. FDA Regulatory Status Of Drugsorb-Atr

Reuters
·
Aug 20

CytoSorbents Corporation Continues Interactive Discussions with FDA on Path Forward for DrugSorb-ATR Market Authorization

Reuters
·
Aug 20

Cytosorbents Corp - FDA Notes Appeal Avenue to Cdrh Director Within 30 Days

THOMSON REUTERS
·
Aug 20

Cytosorbents Corp - FDA Finds No Safety Issues With Drugsorb-Atr, Upholds Denial

THOMSON REUTERS
·
Aug 20

Cytosorbents Corp - FDA Proposes Path Forward for Drugsorb-Atr Market Authorization

THOMSON REUTERS
·
Aug 20

Cytosorbents Corp reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 08

BRIEF-CytoSorbents Q2 Revenue USD 9.617 Million

Reuters
·
Aug 08

CytoSorbents Q2 2025 Results: Revenue Up 9% to $9.6M; Operating Loss Steady at $3.6M

Reuters
·
Aug 08